The PARITY Methods Centre team is thrilled to announce that the PARITY trial enrolled its 120th participant on Tuesday, December 8, thereby reaching 20% of its total enrolment target. There are currently 33 sites open to enrolment across Canada, the United States, Australia, Argentina and South Africa.
The PARITY trial is investigating whether long duration post-operative prophylactic antibiotics decreases the incidence of surgical site infections compared to the standard shorter duration among patients undergoing surgical excision and endoprosthetic reconstruction of lower extremity bone tumors. Led by Dr. Michelle Ghert, PARITY is the first rigorously designed trial in the field of orthopaedic oncology and has the potential to significantly impact clinical practice and establish a collaborative network worldwide for future research in the field. Prior to PARITY, orthopaedic oncologists doubted that prospective multi-center randomized trials were possible in their specialty. The success of the PARITY trial has demonstrated that these types of studies are, in fact, possible.